AI assistant
VERTEX PHARMACEUTICALS INC / MA — Director's Dealing 2024
Feb 8, 2024
29864_dirs_2024-02-08_2d430044-4696-4fa7-9617-b2c86f57ee24.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2024-02-06
Reporting Person: Kewalramani Reshma (Director, CEO & President)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-02-06 | Common Stock | A | 14516 | — | Acquired | 123227 | Direct |
| 2024-02-06 | Common Stock | A | 26972 | — | Acquired | 150199 | Direct |
| 2024-02-07 | Common Stock | A | 20327 | — | Acquired | 170526 | Direct |
Footnotes
F1: Represents earned performance shares with respect to a performance stock unit award granted on 02/03/2021 that contained performance-vesting requirements. The issuer's management development and compensation
committee certified as to the level of performance-goal attainment on 02/06/2024 and the shares will vest on 02/20/2024.
F2: Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2023 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/06/2024 and the shares will vest in installments beginning on 02/10/2024.
F3: Restricted stock unit award that vests in installments beginning on 02/17/2025.